Hematopoietic stem cell transplantation for thalassemia

Immunotherapy

Volumn 4, Issue 9, 2012, Pages 947-956

  Elborai, Yasser ^a,b   Uwumugambi, Alain ^c   Lehmann, Leslie ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b CAIRO UNIVERSITY   (Egypt)

^c Rwinkwavu District Hospital   (Rwanda)

Author keywords

blood transfusion; chelation; gene therapy; iron overload; stem cell transplantation; thalassemia

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE; FERRITIN; FLUDARABINE; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; HYDROXYUREA;

BETA THALASSEMIA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CHELATION THERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; CONTINUOUS INFUSION; DISEASE TRANSMISSION; DRUG HALF LIFE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; GRAFT REJECTION; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IRON OVERLOAD; LIVER BIOPSY; LIVER FAILURE; LIVER INJURY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; THALASSEMIA; THALASSEMIA MAJOR;

BLOOD TRANSFUSION; DEFEROXAMINE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; THALASSEMIA; TRANSPLANTATION CONDITIONING;

EID: 84867378792     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.95     Document Type: Review

References (63)

1. Olivieri NF. The beta-thalassemias. N. Engl. J. Med. 341(2), 99-109 (1999).
2. Cooley TB, Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. N. Engl. J. Med. 37, 29-30 (1925).
3. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood 118(13), 3479-3488 (2011).
4. Whipple GH, Bradford WL. Mediterranean disease-thalassemia (erythroblastic anemia of Cooley): associated pigment abnormalities simulating hemochromatosis. J. Pediatr. 9, 279-311 (1936).
5. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 115(22), 4331-4336 (2010).
6. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull. World Health Organ. 86(6), 480-487 (2008). (Pubitemid 351821761)
7. Giardina P, Forget B. Thalassemia syndromes. In: Hematology: Basic Principles and Practice (5th Edition). Hoffman R, Benz E, Shattil S et al. (Eds). Churchill Livingstone, Philadelphia, PA, USA, 535-563 (2008).
8. Yuan J, Angelucci E, Lucarelli G et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia). Blood 82, 374-377 (1993). (Pubitemid 23206098)
9. Aljurf M, Ma L, Angelucci E et al. Abnormal assembly of membrane proteins in erythroid progenitors of patients with beta-thalassemia major. Blood 87, 2049-2056 (1996). (Pubitemid 26068921)
10. Di Marco V, Capra M, Angelucci E et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood 116(16), 2875-2883 (2010).
11. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Am. Soc. Hematol. Educ. Program 2004(1), 14-34 (2004).
12. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of b-thalassemia major in North America. Blood 104, 34-39 (2004). (Pubitemid 38879833)
13. Fallahian F, Najafi A. Epidemiology of hepatitis C in the Middle East. Saudi J. Kidney Dis. Transpl. 22, 1-9 (2011).
14. Rund D, Rachmilewitz E. b-thalassemia. N. Engl. J. Med. 353, 1135-1146 (2005).
15. Schrier SL, Angelucci E. New strategies in the treatment of the thalassemias. Annu. Rev. Med. 56, 157-171 (2005). (Pubitemid 40299778)
16. Gulati R, Bhatia V, Agarwal SS. Early onset of endocrine abnormalities in beta-thalassemia major in a developing country. J. Pediatr. Endocrinol. Metab. 13, 651-656 (2000). (Pubitemid 30435937)
17. Leung TF, Hung ECW, Lam CWK et al. Bone mineral density in children with thalassaemia major: determining factors and effects of bone marrow transplantation. Bone Marrow Transplant. 36, 331-336 (2005). (Pubitemid 41195166)
18. Li CK, Chik KW, Wong GW, Cheng PS, Lee V, Shing MM. Growth and endocrine function following bone marrow transplantation for thalassemia major. Pediatr. Hematol. Oncol. 21, 411-419 (2004). (Pubitemid 38886670)
19. Wood JC. Magnetic resonance imaging measurement of iron overload. Curr. Opin Hematol. 14(3), 183-190 (2007). (Pubitemid 46597601)
20. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 107(9), 3436-3441 (2006).
21. Borgna-Pignatti C, Rugolotto S, De Stefano P et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89(10), 1187-1193 (2004). (Pubitemid 39390442)
22. Cabantchik ZI, Breuer W, Zanninelli G et al. LPI labile plasma iron in iron overload. Best Pract. Res. Clin. Haematol. 18(2), 277-287 (2005). (Pubitemid 40298370)
23. Cappellini MD, Pattoneri P. Oral iron chelators. Annu. Rev. Med. 60, 25-38 (2009).
24. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88(5), 489-496 (2003). (Pubitemid 36648438)
25. Tanner MA, Galanello R, Dessi C et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115(14), 1876-1884 (2007). (Pubitemid 46598901)
26. Cappellini MD, Cohen A, Piga A et al. A Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107(9), 3455-3462 (2006).
27. Pennell DJ, Porter JB, Cappellini MD et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 115(12), 2364-2371 (2010).
28. Wood JC, Kang BP, Thompson A et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 116(4), 537-543 (2010).
29. Lawson SE, Roberts IA, Amrolia P, Dokal I, Szydlo R, Darbyshira PJ. Bone marrow transplantation for B thalassemia major: the UK experience in two pediatric centers. Br. J. Haematol. 120, 289-295 (2003). (Pubitemid 36194180)
30. Ghanizadeh A, Khajavian S, Ashkani H. Prevalence of psychiatric disorders, depression, and suicidal behaior in child and adolescent with thalassemia major. J. Pediatr. Hematol. Oncol. 28(12), 781-784 (2006). (Pubitemid 44967671)
31. Jawdat DM, Al Saleh S, Sutton P et al. Chances of finding an HLA-matched sibling: the Saudi experience. Biol. Blood Marrow Transplant. 15(10), 1342-1344 (2009).
32. Ghavamzadeh A, Iravani M, Ashouri A et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Biol. Blood Marrow Transplant. 14(3), 301-308 (2008). (Pubitemid 351218201)
33. Resnick IB, Aker M, Tsirigotis P et al. Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen. Bone Marrow Transplant. 40, 957-964 (2007). (Pubitemid 350048194)
34. Lucarelli G, Galimberti M, Polchi P et al. Bone marrow transplantation in patients with thalassemia. N. Engl. J. Med. 322(7), 417-421 (1990). (Pubitemid 20059509)
35. Lucarelli G, Galimberti M, Polchi P et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N. Engl. J. Med. 329(12), 840-844 (1993). (Pubitemid 23267211)
36. Lucarelli G, Clift RA, Galimberti M et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 87(5), 2082-2088 (1996). (Pubitemid 26068926)
37. Mathews V, George B, Deotare U et al. A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with b thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 13(8), 889-894 (2007). (Pubitemid 47055393)
38. Amrolia PJ, Vulliamy T, Vassiliou G et al. Analysis of chimaerism in thalassaemic children undergoing stem cell transplantation. Br. J. Haematol. 114, 219-225 (2001). (Pubitemid 32702658)
39. Andreani M, Nesci S, Lucarelli G et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 25(4), 401-404 (2000). (Pubitemid 30114034)
40. Gaziev J, Sodani P, Lucarelli G et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant. 42, 397-404 (2008).
41. Lucarelli G, Andreani M, Angelucci E. The cure of thalassemia by bone marrow transplantation. Blood Rev. 16, 81-85 (2002). (Pubitemid 34742224)
42. Sabloff M, Chandy M, Wang Z et al. HLA-matched sibling bone marrow transplantation for b-thalassemia major. Blood 117, 1745-1750 (2011).
43. Goussetis E, Peristeri I, Kitra V et al. HLA-matched sibling stem cell transplantation in children with b-thalassemia with anti-thymocyte globulin as part of the preparative regimen: the Greek experience. Bone Marrow Transplant. 47(8), 1061-1066 (2012).
44. Ghavamzadeh A, Iravani M, Ashouri A et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Biol. Blood Marrow Transplant. 14(3), 301-308 (2008). (Pubitemid 351218201)
45. Chandy M. Stem cell transplantation in India. Bone Marrow Transplant. 42(Suppl. 1), S81-S84 (2008).
46. Borgna-Pignatti C, Marradi P, Rugolotto S, Marcolongo A. Successful pregnancy after bone marrow transplantation for thalassaemia. Bone Marrow Transplant. 18(1), 235-236 (1996). (Pubitemid 26289664)
47. Angelucci E, Muretto P, Nicolucci A et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100, 17-21 (2002). (Pubitemid 35177422)
48. Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann. Intern. Med. 136(9), 667-672 (2002). (Pubitemid 34462679)
49. Dahllöf G, Hingorani SR, Sanders JE. Late effects following hematopoietic cell transplantation for children. Biol. Blood Marrow Transplant. 14, 88-93 (2008). (Pubitemid 350286848)
50. Caocci G, Pisu S, Argiolu F et al. Decision-making in adult thalassemia patients undergoing unrelated bone marrow transplantation: quality of life, communication and ethical issues. Bone Marrow Transplant. 37, 165-169 (2006). (Pubitemid 43108808)
51. Kelly MJ, Pennarola BW, Rodday AM, Parsons SK. Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT). Pediatr. Blood Cancer 59(4), 725-731 (2012).
52. Sodani P, Gaziev D, Polci P et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 104, 1201-1203 (2004). (Pubitemid 39038044)
53. Eapen M, Rubinstein P, Zhang MJ et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J. Clin. Oncol. 24, 145-151 (2006). (Pubitemid 46630506)
54. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant. 35, 225-231 (2005). (Pubitemid 40268292)
55. Remberger M, Storer B, Ringden O, Anasetti C. Association between pretransplant thymoglobulin and reduced non-relapse mortality after marrow transplantation from unrelated donors. Bone Marrow Transplant. 29, 391-397 (2002). (Pubitemid 34257712)
56. Bernardo ME, Piras E, Vacca A et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 120(2), 473-476 (2012).
57. Boncimino A, Bertaina A, Locatelli F. Cord blood transplantation in patients with hemoglobinopathies. Transfus. Apher. Sci. 42(3), 277-281 (2010).
58. Ruggeri A, Eapen M, Scaravadou A et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol. Blood Marrow Transplant. 17(9), 1375-1382 (2011).
59. Sodani P, Isgrò A, Gaziev J et al. Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood 115, 1296-1302 (2010).
60. Evans PC, Lambert N, Maloney S, Furst DE, Moore JM, Nelson JL. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood 93(6), 2033-2037 (1999). (Pubitemid 29128506)
61. Ichinohe T, Maruya E, Saji H. Long-term feto-maternal microchimerism: nature's hidden clue for alternative donor hematopoietic cell transplantation? Int. J. Hematol. 76(3), 229-237 (2002). (Pubitemid 43020311)
62. Til N, Boer H, Mashamba N et al. Correction of murine rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene. Mol. Ther. doi:10.1038/mt.110 (2012) (Epub ahead of print).
63. Cavazzana-Calvo M, Payen E, Negre O et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467, 318-322 (2010).